Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database

British Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2010, Pages 85-94

  Lodi, Sara ^a   Evans, Stephen J W ^a   Egger, Peter ^b   Carpenter, James ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Claims database; Cohort study; Rheumatoid arthritis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STEROID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LOGISTIC MODELS; PROPORTIONAL HAZARDS MODELS;

EID: 72949109749     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03560.x     Document Type: Article

References (30)

1. 4S investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 1389.
2. Shepherd J, Cobbe SM, Ford I, Isle CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 : 1301 1308.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold MO, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 335 : 1001 1009.
4. The Long-Term intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 : 1349 1357.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279 : 1615 1622.
6. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, and the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcome Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 361 : 1149 1158. (Pubitemid 36398384)
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
8. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003 2 : 517 526.
9. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators. Circulation 1999 100 : 230 235.
10. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles S, Gotto AM. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001 344 : 1959 1965.
11. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000 6 : 1399 1402.
12. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005 4 : 977 987.
13. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999 353 : 983 984.
14. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakova O, Ford I, Capell H, Sattar N. Trial of atorvastatin in rheumatoid arthritis (TARA): a double-blind, randomised placebo-controlled trial. Lancet 2004 363 : 2015 2021.
15. Klareskog L, Hamsten A. Statins in rheumatoid arthritis - two birds with one stone? Lancet 2004 363 : 2011 2012.
16. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003 170 : 1524 1530.
17. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005 14 : 443 451.
18. Therneau TM, Grambsch PM. Modelling Survival Data. Extending the Cox Model. New York : Springer-Verlag, 2000 127 148.
19. Barsante MM, Roffê E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, Salete De A, Castro M, Teixeira MM. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 2005 516 : 282 289.
20. Chang LT, Sun CK, Chiang CH, Wu CJ, Chua S, Yip HK. Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. J Cardiovasc Pharmacol 2007 49 : 20 6.
21. Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 2007 27 : 631 639.
22. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage N, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995 333 : 621 627.
23. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomised trial. Circulation 1997 96 : 1398 1402.
24. Kobashigawa JA, Moriguchi JD, Laks H, Wener L, Hage A, Hamilton MA, Cogert G, Marquez A, Vassilakis ME, Patel J, Yeatman L. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005 24 : 1736 1740.
25. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004 363 : 1607 1608. (Pubitemid 38625664)
26. Hackam DG, Mamdani M, Li P, Redelmeier D. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006 367 : 413 418.
27. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009 68 : 546 551.
28. García-Martínez A, Hernández-Rodríguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Care Res 2004 51 : 674 678.
29. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006 35 : 1301 1308.
30. Setoguchi S, Avorn J, Schneeweiss S. Statins and the risk of colorectal cancer. N Engl J Med 2005 353 : 952.